MTPConnect, through the Australian Antimicrobial Resistance Network (AAMRNet), and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) combined resources to develop this report to improve current estimates of the mortality burden of AMR in Australia.
'Antimicrobial Resistance (AMR) Impact Report: How big is Australia's AMR threat?' delves deeper into the gaps in our data collection methods to find out how many people are dying from drug-resistant infections in Australia.
The report was launched to coincide with 'World Antimicrobial Awareness Week 2022', a global campaign held annually from 18-24 November. WHO has identified antimicrobial resistance (AMR) as one of the top 10 global public health threats.
AMR deaths are hard to estimate, in part because they can be hidden behind other conditions, such as cancer. The report's modelling, derived from published studies, suggests it could be anywhere from 2.4 to 18 times higher than previously thought.
It highlights the challenge of measuring the true impact of AMR and makes some recommendations on how to improve data collection in Australia, to best inform strategies and interventions to combat this critical threat.
Better information can drive improved policy settings and targeted interventions.
The Australian Antimicrobial Resistance Network (AAMRNet), is a multi-stakeholder expert group formed to address the impact of antimicrobial resistance (AMR) on human health. Established in 2020 and operated by MTPConnect, the Industry Growth Centre for the Medical Technology, Biotechnology and Pharmaceutical sector, AAMRNet is also supported by Pfizer ANZ, CSIRO, MSD Australia, GSK Australia, Botanix Pharmaceuticals, Recce Pharmaceuticals, Medicines Australia, SpeeDx, Tenmile, Biointelect, Monash Centre to Impact AMR and Bugworks Australia.
Commonwealth Scientific and Industrial Research Organisation (CSIRO) is Australia's national science agency.